Al­ler­gan bags two new deals, takes op­tion to buy Lyso­so­mal Ther­a­peu­tics and pays $50M for mi­cro­bio­me pact

Kees Been

Al­ler­gan swooped in­to JP Mor­gan bear­ing news of a pair of deals, ink­ing an ex­clu­sive op­tion to buy out Lyso­so­mal Ther­a­peu­tics for its neu­rode­gen­er­a­tion pipeline and pay­ing $50 mil­lion up­front to part­ner with As­sem­bly Bio on the mi­cro­bio­me.

Al­ler­gan bought the op­tion on Lyso­so­mal Ther­a­peu­tics — run by Kees Been — peg­ging an un­spec­i­fied price for the biotech af­ter the Phase Ib comes through with da­ta on Parkin­son’s dis­ease for their drug LTI-291. Al­ler­gan, which is not in the least bit re­luc­tant to pay a pre­mi­um for what it wants, al­so added some fi­nan­cial sup­port for R&D at the com­pa­ny, but de­clined to spell out the de­tails.

LTI has been de­vel­op­ing small mol­e­cules that cross the blood-brain bar­ri­er and in­crease GCase ac­tiv­i­ty — cor­rect­ing lyso­so­mal en­zyme glu­co­cere­brosi­dase mu­ta­tions that can cause the buildup of lipids in cells — to po­ten­tial­ly treat the root cause of Parkin­son’s.

Al­ler­gan paid $50 mil­lion up­front to part­ner with In­di­anapo­lis-based As­sem­bly Bio­sciences on two pre­clin­i­cal drugs aimed at ul­cer­a­tive col­i­tis and Crohn’s dis­ease. Al­ler­gan will al­so get world­wide rights for two more can­di­dates fo­cused on ir­ri­ta­ble bow­el syn­dromes.

Al­ler­gan will share ear­ly de­vel­op­ment costs on these pro­grams, then takes con­trol af­ter proof-of-con­cept.

The vast land­scape of the mi­cro­bio­me has be­come a key field for a new wave of biotechs look­ing to mod­u­late dis­ease by tar­get­ing mi­crobes that pop­u­late the gut. It’s still large­ly an ear­ly-stage area, though, putting Al­ler­gan in with an ear­ly-stage col­lab­o­ra­tion to help beef up a rapid­ly grow­ing pipeline.

Over the past year Al­ler­gan CEO Brent Saun­ders has been on a tear, buy­ing up or part­ner­ing a range of pro­grams as he looks to con­struct a ma­jor pipeline for new prod­uct de­vel­op­ment.

“The mi­cro­bio­me — the mi­cro­bial pop­u­la­tions that col­o­nize the hu­man body — is rapid­ly gain­ing promi­nence in nu­mer­ous fields of re­search rel­e­vant to Al­ler­gan’s key ar­eas of fo­cus, in­clud­ing GI dis­or­ders,” said David Nichol­son, Chief R&D Of­fi­cer, Al­ler­gan.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vicente Anido (University of West Virginia via YouTube)

Aerie fires CEO af­ter lead pro­gram flop, com­ments about pri­ma­ry end­points be­ing 'not re­quired'

Aerie Pharmaceuticals CEO Vicente Anido has left the company less than a week after trying to chart a Phase III study in the wake of a serious Phase IIb flop.

Anido’s last day at Aerie was Friday, the biotech announced in a news release Tuesday morning, and Benjamin McGraw is taking his place in an interim role. The now former CEO was terminated without cause, according to an SEC filing.

The board has started looking for a full-time chief to take his place.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

When ef­fi­ca­cy is bor­der­line: FDA needs to get more con­sis­tent on close-call drug ap­provals, agency-fund­ed re­search finds

In the exceedingly rare instances in which clinical efficacy is the only barrier to a new drug’s approval, new FDA-funded research from FDA and Stanford found that the agency does not have a consistent standard for defining “substantial evidence” when flexible criteria are used for an approval.

The research comes as the FDA is at a crossroads with its expedited-review pathways. The accelerated approval pathway is under fire as the agency recently signed off on a controversial new Alzheimer’s drug, with little precedent to explain its decision. Meanwhile, top officials like Rick Pazdur have called for a major push to simplify and clarify all of the various expedited pathways, which have grown to be must-haves for sponsors of nearly every newly approved drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Jay Bradner (Jeff Rumans for Endpoints News)

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

Right about a year ago, a Novartis team led by Jay Bradner and Cynthia Grosskreutz at NIBR swooped in to scoop up a Cambridge, MA-based opthalmology gene therapy company called Vedere. Their focus was on a specific market niche: inherited retinal dystrophies that include a wide range of genetic retinal disorders marked by the loss of photoreceptor cells and progressive vision loss.

But that was just the first deal that whet their appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Take­da snaps up the Japan­ese rights to an old Shire cast-off; Boehringer In­gel­heim ac­quires Abexxa Bi­o­log­ics

A week before the FDA is set to decide on Mirum Pharmaceuticals’ lead liver disease drug — an old Shire cast-off called maralixibat — Takeda is swooping in to secure the rights in Japan.

Maralixibat’s roots trace back to Lumena, which was snapped up by Shire for $260 million-plus back in 2014. While the candidate had failed mid-stage studies at Shire, Mirum believes better trial design and patient selection will deliver the wins it needs. The drug is currently in development for Alagille syndrome (a condition called ALGS in which bile builds up in the liver), progressive familial intrahepatic cholestasis (PFIC, which causes progressive liver disease) and biliary atresia (a blockage in the ducts that carry bile from the liver to the gallbladder).

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.